Lung adenocarcinoma: genes and variants
Explore variant evidence for Lung adenocarcinoma across 16 analyzed proteins (BRAF, ERBB2, ROS1, TP53, ARID1A and 11 more). Linked ClinVar records include 9 pathogenic or likely pathogenic variants, 6 variants of uncertain significance and 2 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-04. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Lung adenocarcinoma
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
3 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRAF have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
ERBB2: Receptor tyrosine-protein kinase erbB-2
ERBB2, also called HER2, is a cell-surface receptor tyrosine kinase that works with other ERBB receptors to transmit growth signals. It helps organize signaling and cytoskeletal responses, and abnormal ERBB2 activity is a major feature of several cancers.
3 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ERBB2 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
ROS1: Proto-oncogene tyrosine-protein kinase ROS
Its normal physiologic signaling remains incompletely defined, but chromosomal rearrangement can place its kinase domain under constitutive control. ROS1 fusion kinases are actionable oncogenic drivers in non-small-cell lung cancer and several other tumors.
2 ClinVar pathogenic / likely pathogenic and 2 uncertain variants in ROS1 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
TP53: Cellular tumor antigen p53
It coordinates transcriptional responses to DNA damage and other cellular stresses, promoting cell-cycle arrest, senescence, DNA repair, or apoptosis when appropriate. Loss of this tumor-suppressive control is one of the most common events in cancer, while germline pathogenic variants cause Li-Fraumeni syndrome.
0 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in TP53 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
ARID1A: AT-rich interactive domain-containing protein 1A
It helps BAF chromatin-remodeling complexes open or reposition nucleosomes at regulatory regions and thereby control lineage-specific transcription. Somatic loss is frequent in several cancers, while germline haploinsufficiency can cause Coffin-Siris syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ARID1A have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
CDKN2A: Tumor suppressor ARF
The ARF product of CDKN2A is a tumor-suppressor protein that binds MDM2 and helps preserve p53 activity. By promoting cell-cycle arrest and apoptosis, it provides an important barrier to uncontrolled cell growth from within the nucleolus.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CDKN2A have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
EGFR: Epidermal growth factor receptor
A cell-surface receptor tyrosine kinase that responds to epidermal-growth-factor family ligands. Ligand binding activates phosphorylation cascades that regulate cell growth, survival, and differentiation, which is why EGFR changes are important in cancer biology.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in EGFR have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
KEAP1: Kelch-like ECH-associated protein 1
It continuously targets NRF2 for degradation under basal conditions but releases this brake when reactive electrophiles or oxidative stress modify KEAP1. Somatic loss-of-function variants can lock tumors into a persistent antioxidant state that promotes survival and treatment resistance.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in KEAP1 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
KRAS: GTPase KRas
A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in KRAS have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
RB1: Retinoblastoma-associated protein
It restrains E2F-dependent transcription and prevents inappropriate G1-to-S cell-cycle progression until proliferative signals are appropriate. Loss of function is a fundamental cancer-driving event, while germline pathogenic variants cause hereditary retinoblastoma and increase risk of additional tumors.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RB1 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
RBM10: RNA-binding protein 10
It regulates alternative pre-mRNA splicing and influences expression of proteins controlling cell growth, apoptosis, and differentiation. Loss-of-function variants cause TARP syndrome, while somatic inactivation is recurrent in lung adenocarcinoma and other cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RBM10 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
SMARCA4: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4
Its ATPase activity drives nucleosome remodeling in BAF-family complexes and thereby controls access to regulatory DNA. Germline pathogenic variants cause Coffin-Siris syndrome or rhabdoid-tumor predisposition, while somatic loss defines several aggressive cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in SMARCA4 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
STK11: Serine/threonine-protein kinase STK11
It activates AMPK-family kinases to coordinate cellular energy sensing, polarity, and growth restraint. Germline loss-of-function variants cause Peutz-Jeghers syndrome and its associated cancer predisposition, while somatic loss is common in lung and other cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in STK11 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
TERT: Telomerase reverse transcriptase
It extends telomeric DNA using an internal RNA template and helps counter progressive chromosome-end shortening in stem and proliferative cells. Loss-of-function variants cause telomere-biology disorders, while promoter activation and increased activity support unlimited proliferation in many cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TERT have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
U2AF1: Splicing factor U2AF 35 kDa subunit
It recognizes the AG dinucleotide at 3-prime splice sites during early spliceosome assembly. Recurrent S34 and Q157 hotspot mutations alter splice-site selection and are important drivers of myelodysplastic syndromes, AML, and some solid tumors.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in U2AF1 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
CDK12: Cyclin-dependent kinase 12
It promotes transcription of long DNA-repair and genome-maintenance genes through RNA-polymerase-II phosphorylation. Loss-of-function alterations occur in prostate, ovarian, and other cancers and can create a characteristic pattern of genomic instability.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CDK12 have source records linked to Lung adenocarcinoma. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): TLR4 and APC.
ClinVar pathogenic and likely pathogenic variants linked to Lung adenocarcinoma
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| ROS1 G1135R | 1135 | Fibronectin type-III 5 | Pathogenic / likely pathogenic (★) |
| ERBB2 L836R | 836 | Protein kinase | Pathogenic / likely pathogenic |
| BRAF G466V | 466 | Protein kinase | Pathogenic / likely pathogenic |
| BRAF G469V | 469 | Protein kinase | Pathogenic / likely pathogenic |
| BRAF L597R | 597 | Protein kinase | Pathogenic / likely pathogenic |
| ROS1 G2032R | 2032 | Protein kinase | Pathogenic / likely pathogenic |
| CDK12 G879V | 879 | Protein kinase | Pathogenic / likely pathogenic |
| ERBB2 L755P | 755 | Protein kinase | Pathogenic / likely pathogenic |
| ERBB2 L869R | 869 | Protein kinase | Pathogenic / likely pathogenic |
Which prediction tools work for Lung adenocarcinoma
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 99 out of 100
- ESM1b (LLR): 98 out of 100
- CATVariant: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- RASopathy also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Lung adenocarcinoma variants (36 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Lung adenocarcinoma variants (26 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Lung adenocarcinoma variants (17 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Lung adenocarcinoma variants (11 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Lung adenocarcinoma variants (10 pathogenic / likely pathogenic).
- Urinary bladder cancer also has ClinVar records linked to ERBB2 variants; they fall mostly in different places as the Lung adenocarcinoma variants (6 pathogenic / likely pathogenic).
Diseases related to Lung adenocarcinoma
- Non-small cell lung carcinoma, also linked to BRAF, CDKN2A, EGFR, ERBB2 and 7 more
- Urinary bladder cancer, also linked to ARID1A, CDKN2A, EGFR, ERBB2 and 4 more
- Colorectal cancer, also linked to ARID1A, BRAF, EGFR, ERBB2 and 2 more
- Hepatocellular carcinoma, also linked to ARID1A, BRAF, CDKN2A, RB1 and 2 more
- Acute myeloid leukemia, also linked to KRAS, TERT, TP53 and U2AF1
- Hereditary breast ovarian cancer syndrome, also linked to CDK12, KRAS, STK11 and TP53
- Melanoma, cutaneous malignant, also linked to BRAF, CDKN2A, STK11 and TERT
- Lung cancer, also linked to BRAF, EGFR, ERBB2 and KRAS
- Head and neck squamous cell carcinoma, also linked to CDKN2A, EGFR, SMARCA4 and TP53
- Gastric cancer, also linked to ERBB2, KRAS and TP53
- Multiple myeloma, also linked to BRAF, KRAS and TP53
- Esophageal cancer, also linked to ARID1A, CDKN2A and TP53
Frequently asked questions
Which genes have records linked to Lung adenocarcinoma?
This view contains 16 analyzed proteins: BRAF, ERBB2, ROS1, TP53, ARID1A and 11 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 9 pathogenic or likely pathogenic variants, 6 variants of uncertain significance and 2 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 17 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center